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Abstract: Background and Objectives: Given the considerable spatial, temporal, and ecological
factors, heterogeneity, which affects emergency response, persistence, and dissemination of genetic
determinants that confer microorganisms their resistance to antibiotics, several authors claim that
antibiotics’ resistance must be perceived as an ecological problem. The aim of this study was to
determine the prevalence of broad-spectrum bla genes, not only Extended-spectrum β-lactamases
(ESBL) but also AmpC-types, in clinical strains of Escherichia coli isolated from Portugal (in the highest
region of the country, Serra da Estrela) to disclose susceptibility profiles among different genotypes,
and to compare the distribution of bla genes expressing broad-spectrum enzymes. Materials and
Methods: Clinical strains of Escherichia coli presenting resistance to third generation (3G) cephalosporins
and susceptibility to inhibition by clavulanic acid were studied by means of phenotypic and molecular
profiling techniques for encoding β-lactamases genes. Results: Strains were mainly isolated from
hospital populations (97%). Molecular analysis enabled the detection of 49 bla genes, in which 55%
(27/49) were identified as blaOXA-1-like, 33% (16/49) as blaCTX-M-group-1, 10% (5/49) as blaTEM, and 2%
(1/49) were identified as genes blaCIT (AmpC). Among all blaOXA-1-like detected, about 59% of strains
expressed at least another bla gene. Co-production of β-lactamases was observed in 40% of strains,
with the co-production of CTX-M group 1 and OXA-1-like occurring as the most frequent. Conclusions:
This is the first study using microorganisms isolated from native people from the highest Portuguese
mountain regions, showing an unprecedent high prevalence of genes blaOXA-1-like in this country.
Keywords: β-lactamases; ESBL; AmpC; Escherichia coli; resistance mechanisms; Serra da Estrela
1. Introduction
The excessive use of antibiotics in recent years has become an emerging problem across many
sectors—public health, economic, and social [1]. Associated with large-scale population movements
and the development of industrialization, the current excessive use of antibiotics is the major cause of
strains developing mechanisms, consequently causing increased morbidity, mortality, and therapeutic
costs [2–5].
Extended-spectrum β-lactamases (ESBLs) have been widely described and their epidemiology
and geographic prevalence is the subject of continuous study [6]. Known for their resistance to third
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generation (3G) cephalosporins, inhibition by clavulanic acid, and plasmid encoding, ESBLs represent
a set of various types of enzymes that differ in origin, amino acid sequence, or hydrolytic activity on
β-lactams [1]. The most widespread ESBL variants, especially in strains of Escherichia coli, are the TEM-,
SHV-, CTX-M-, and OXA-types [7–9].
TEM was first discover in 1963 and named after Greek patient, Temionera. Since then, genetic
variations of TEM have been described. The first TEM enzyme was named as TEM-1, and nowadays
there are over 230 different-TEMs [10]. These enzymes differ in genetic nucleotide missense
polymorphisms, thus altering amino acid sequence (Figure 1) and kinetic properties [11].
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During the 1990 decade, the TEM- and SHV-type variants were the most prevalent worldwide,
with the exception of South America, where the CTX-M-2 was dominant. In that decade, the spread of
the TEM- and SHV-type ESBLs were taking place, mostly by endemic clones, with Klebsiella pneumoniae
being the main carrier of blaESBL genes [8]. The ESBL-producing strains were essentially isolated in
healthcare-associated infections (HAI), with high frequency in Intensive Care Units (ICU) and low
incidence in community-acquired infections (CAI) [12].
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The first epidemiological change began with the spread of the CTX-M-type ESBL [13]. With an
extended hydrolytic action and using E. coli as a carrier, this type of ESBL became more frequently noted
in several parts of the world and in different settings—both HAI and CAI [14]. However, in the middle
of the century there was a drastic change in the epidemiology of ESBL-resistance as a consequence of
these variants [2].
Throughout this decade, the CTX-M-type ESBLs were the most prevalent β-lactamases in
most European, Asian, and South American countries, and in some cases they are even considered
endemic [14–16]. Despite this wide distribution, mostly due to the CTX-M-15 variant, other variants
are locally amplified, such as CTX-M-9 and CTX-M-14 in Spain, CTX-M-1 in Italy, CTX-M-5 in Belarus
and Russia, and CTX-M-3 in Eastern Countries [2,7]
OXA β-lactamases were described for the first time in a strain of Pseudomonas aeruginosa and
showed a low hydrolytic activity on 3G cephalosporins and weak inhibition by clavulanic acid, thus
presenting almost no clinical relevance [17]. However, occasional mutations in blaOXA genes have
caused variants of these enzymes with ESBL phenotypes, extending their spectrum of activity but
maintaining their weak inhibition to clavulanic acid. OXA-1 and OXA-1-like (OXA-1, OXA-4, OXA-30)
variants are examples of these enzymes [18]. Despite more than 220 OXA β-lactamases having been
described [10], not all present the ESBL phenotype.
The emerging spread of ESBL-producing strains is currently associated with the production of
AmpC β-lactamases. These enzymes are cephalosporinases with inductive activity belonging to the
Ambler class C [19,20]. With hydrolytic activity on penicillin and 3G cephalosporins and susceptibility
to fourth generation (4G) cephalosporins (cefepime and cefpirome), AmpCs differ from the ESBLs in
their hydrolytic action on cephamycins (cefoxitin and cefotetan) and non-susceptibility to clavulanic
acid. In contrast to ESBLs, the AmpCs enzymes are only inhibited by cloxacillin or boronic acid [21–23].
Originally described as chromosomal β-lactamases, their plasmid encoding is now recognized [24].
AmpCs that are plasmid-mediated are a derivation from the chromosomal enzymes and can co-exist in
chromosomal positive strains, such as E. coli, increasing their expression [25]. CMY-1 was discovered
in South Korea (1989) and was the first plasmid-mediated AmpC [22]. Since then, many different types
of plasmid-mediated AmpCs (CIT, DHA, MOX, EBC, FOX, and ACC) have been described, with the
CMY-2 enzyme (CIT-type AmpC) being considered the most widespread variant [23,25,26].
The infections caused by ESBL- and AmpC-producing-strains were initially exclusive to HAI,
but now they are also found in CAI [14].
Another reason for the resistance to β-lactams and to the emerging spread lies in the phenomenon
of co-production of β-lactamases. The ability to produce different variants or types of β-lactamases
gives the bacteria an extended resistance profile. This fact, along with the difficulty in detecting these
phenomena by phenotyping techniques usually applied in hospital laboratories, decreases the viability
of the commonly used antibiotherapies, and therefore, allows for the spread of these enzymes [27–29].
In Portugal, several studies have been conducted in order to describe the epidemiology, prevalence,
and emerging spread of variants, in particular the β-lactamase-producing strains with possibility of
resistance. Several Portuguese regions, such as the north and central, have been targeted by these
studies [7,9,18,30–33]. However, due to constant epidemiological changes and to the absence of studies
in other regions, this purpose has not yet been completely achieved.
This work aims to assess the prevalence of ESBLs and AmpCs in clinical isolates of E. coli in
the region of Serra da Estrela, Portugal. Additionally, it intends to determine the most prevalent bla
gene in this region; to provide evidence for the co-production phenomena, as well as its frequency
and prevalence, and to compare antibiotic susceptibility profiles among different genotypes and to
understand the distribution of bla genes in different settings, nosocomial (HAI), and community
environments (CAI).
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2. Materials and Methods
2.1. Bacterial Strains
In the present study, strains of E. coli (n = 38) with resistance or low susceptibility to 3G
cephalosporins detected in the Service of Clinical Pathology, Sousa Martins Hospital, ULS Guarda,
Portugal, from July 2010 to May 2011, were analyzed. These strains were isolated from different
biological specimens derived from different settings—HAI and CAI.
2.2. Phenotype Identification and Antibiotics Susceptibility
Bacterial identification and antibiotic susceptibility profiles were determined by the Vitek®2
(bioMérieux®, Marcy-l’Étoile, France) automated system, using the ID GN card (bioMérieux®,
Marcy-l’Étoile, France) for identification of Gram-negative susceptibility, and then the AST N151 card
(bioMérieux®, Marcy-l’Étoile, France) for Gram-negative susceptibility. The susceptibility to cefoxitin
(not evaluated by the AST N151 card) was analyzed using the disk diffusion method (Kirby-Bauer
method), according to the standards of the Clinical and Laboratory Standards Institute (CLSI) for the
determination of minimum inhibitory concentrations (MIC) [34]. Briefly, the susceptibility to this
cephamycin was tested with a cefoxitin disk (30 µg) and confirmed whenever a halo diameter higher
than 18 mm was observed. This criterion is mentioned by several authors as a screening method for
the detection of AmpC-type β-lactamase producing strains [35].
The production of ESBLs was evaluated by E-test (bioMérieux®, France): E-test cefotaxime and
cefotaxime/clavulanic acid (CT/CTL) and the E-test ceftazidime and ceftazidime/clavulanic acid (TZ/TZL).
The production of ESBLs were determined as positive whenever the MIC ratio was equal to or higher
than 8 (CT/CTL or TZ/TZL ≥ 8), or if there was a phantom zone or an ellipse deformation, according to the
manufacturer’s instructions. Similarly, the screening for AmpC β-lactamases production was determined
by E-test (bioMérieux®, Marcy-l’Étoile, France): cefotetan and cefotetan/cloxacillin (CN/CNI).
2.3. Molecular Characterization of bla Genes
A set of three multiplex Polymerase Chain Reaction (PCR) assays and a simple PCR assay was
used for the amplification of the most frequent bla genes in E. coli strains, as described by Dallenne et
al. (2010) and represented in Table 1 [36].
The reaction mixture was prepared with 1µL (2ng) of DNA in a total 25µL of master mix with
a 1xPCR buffer (10 mM Tris-HCl, pH 8.3/50 mM KCl), 200µM of each dNTP (deoxyribonucleotide
triphosphate mix), 1.5 mM MgCl2, a variable concentration of specific primers, and 0.5U of Taq polymerase.
The amplification occurred under the following conditions: initial denaturation at 94 ◦C for 10 min;
30 cycles at 94 ◦C for 40 s, at 60 ◦C for 40 s, at 72 ◦C for 1 min, final elongation at 72 ◦C for 7 min,
and holding temperature at 4 ◦C.
Amplified products were evaluated by 2% agarose gel containing SYBR green (SYBR®Green
I, SigmaAldrich, Spain) electrophoresis, which ran at 80V for 4 h in 1xTAE [4.844 g/L of
2-Amino-2-hydroxymethyl-propane-1,3-diol (TRIS base), 1.21 ml/L of of glacial acetic acid, 0.372 g/L of
2,2’,2”,2”’-(Ethane-1,2-diyldinitrilo)tetraacetic acid (EDTA) sodium salt, pH 8.0]. The visualization of
the fragments was carried out in the UV transilluminator, where the molecular weight was inferred
through a molecular weight marker (100 bp), allowing for the identification of the enzyme.
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Table 1. Sequences of primers used for extended-spectrum β-lactamases (ESBL) and AmpC bla genes in
the present study. Adapted from a previous study [36].
PCR Multiplex Targeted β-lactamases Primer’s Name Sequence (5′-3′) Product’sSize (bp)
PCR multiplex
TSO (TEM, SHV,
and OXA-1-like)
TEM variants (including TEM-1
and TEM-2)
MultiTSO-T_for CATTTCCGTGTCGCCCTTATTC
800MultiTSO-T_rev CGTTCATCCATAGTTGCCTGAC
SHV variants (including SHV-1) MultiTSO-S_for AGCCGCTTGAGCAAATTAAAC 713MultiTSO-S_rev ATCCCGCAGATAAATCACCAC
OXA-1-like variants OXA-1,
OXA-4 and OXA-30
MultiTSO-O_for GGCACCAGATTCAACTTTCAAG
564MultiTSO-O_rev GACCCCAAGTTTCCTGTAAGTG
PCR multiplex
CTX-M (CTX-M
Group 1, CTX-M
Group 2, and
CTX-M Group 9)
CTX-M Group 1 variants
(including CTX-M-1, CTX-M-3
and CTX-M-15)
MultiCTX-MGrp1_for TTAGGAARTGTGCCGCTGYAa
688
MultiCTX-MGrp1-2_rev CGATATCGTTGGTGGTRCCATa
CTX-M Group 2 variants MultiCTX-MGrp2_for CGTTAACGGCACGATGAC 404MultiCTX-MGrp1-2_rev CGATATCGTTGGTGGTRCCATa
CTX-M Group 9 variants
(including CTX-M-9 and
CTX-M-14)
MultiCTX-MGrp9_for TCAAGCCTGCCGATCTGGT
561
MultiCTX-MGrp9_rev TGATTCTCGCCGCTGAAG
PCR CTX-M
Group 8/25
CTX-M Group 8/25 variants
CTX-M-8, CTX-M-25, CTX-M-26,
and CTX-M-39 to CTX-M-41
CTX-MGrp8/25_for AACRCRCAGACGCTCTACa
326
CTX-MGrp8/25_rev TCGAGCCGGAASGTGYATa
PCR multiplex
AmpC (ACC, FOX,
MOX, DHA, CIT,
and EBC)
ACC variants ACC-1 and
ACC-2
MultiACC_for CACCTCCAGCGACTTGTTAC
346MultiACC_rev GTTAGCCAGCATCACGATCC
FOX variants FOX-1 to FOX-5
MultiFOX_for CTACAGTGCGGGTGGTTT
162MultiFOX_rev CTATTTGCGGCCAGGTGA
MOX variants MOX-1, MOX-2,
CMY-1, CMY-8 to CMY-11, and
CMY-19
MultiMOX_for GCAACAACGACAATCCATCCT
895
MultiMOX_rev GGGATAGGCGTAACTCTCCCAA
DHA variants DHA-1 and
DHA-2
MultiDHA_for TGATGGCACAGCAGGATATTC
997
MultiDHA_rev GCTTTGACTCTTTCGGTATTCG
CIT variants LAT-1 to LAT-3,
BIL-1, CMY-2 to CMY-7, CMY-12
to CMY-18, and CMY-21 to
CMY-23
MultiCIT_for CGAAGAGGCAATGACCAGAC
538
MultiCIT_rev ACGGACAGGGTTAGGATAGYa
EBC variants ACT-1 and MIR-1
MultiEBC_for CGGTAAAGCCGATGTTGCG
683MultiEBC_rev AGCCTAACCCCTGATACA
a Y = T or C; R = A or G; PCR—Polymerase chain reaction; bp—base pairs.
3. Results
Phenotypic susceptibility to antimicrobials, as well as molecular characterization of E. coli isolated
from the region of Serra da Estrela, Portugal, are shown in Table 1.
3.1. Bacterial Strains
In the present study, 38 strains of E. coli were harvested, isolated, and studied. About 97% (37/38)
of strains were isolated from HAI, supporting the literature that highlights the hospital setting as
prevailing when referring to multi-resistant bacteria [14]. Only 3% were isolated from CAI. Strains
were isolated mainly from urinary infections with a frequency of 68% (26/38), 18% (7/38) from soft
tissue and skin infections, 10% (4/38) from respiratory infections, and 3% (1/38) from the bloodstream.
3.2. Phenotype Identification and Antibiotic Susceptibility
The susceptibility to antimicrobial agents was carried out on Vitek®2 (bioMérieux®) and confirmed
an extended profile of resistance to several antibiotics. Besides ampicillin (inclusion criterion),
all of the strains presented resistance to other β-lactams, in particular cephalotin and cefuroxime
(2ndG cephalosporins), cefotaxime, and ceftazidime (3G cephalosporins), and all were susceptible to
ertapenem and meropenem, which are carbapenems (Table 2).
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Table 2. Phenotypic and molecular characterization of Escherichia coli strains isolated from Serra da Estrela (Portugal) resistant to ampicillin (AMP).
Strain Source
Antibiogram
Presumptive Tests Confirmatory
ESBL AmpC Molecular Tests
Etest FOX Etest PCR
AMP AMC TZP CXM CT TZ ERT MEM GEN CIP LVX TIG SXT CT/CTL TZ/TZL Diameter CN/CNI
ESBL AmpCMIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) MIC (mg/L) ratio ratio (mm) ratio
A1 Urine HAI ≥32 R 4 ≤4 >64 R >64 R 16 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 ≤20 >8 + >8 + 27 <8 N.D. N.D.
A2 Urine HAI ≥32 R ≥32 R ≥128 R >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 40 >8 + >8 + 23 <8 OXA-1-like N.D.
A3 Respiratory HAI ≥32 R 16 ≤4 >64 R >64 R 16 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R 1 ≤20 >8 + P.Z. + 24 <8 OXA-1-like N.D.
A4 Urine HAI ≥32 R 4 ≤4 >64 R >64 R 16 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 ≤20 >8 + >8 + 25 <8 N.D. N.D.
A5 Urine HAI ≥32 R 16 ≥128 R >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≤20 P.Z. + P.Z. + 24 <8 N.D. N.D.
A6 Urine HAI ≥32 R 4 ≤4 >64 R >64 R 16 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 ≤20 P.Z. + >8 + 24 <8 CTX-M Grp1 + OXA-1-like N.D.
A7 Respiratory HAI ≥32 R 16 8 >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 40 >8 + >8 + 16 + <8 CTX-M Grp1 N.D.
A8 Urine HAI ≥32 R ≥32 R ≥128 R >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 40 >8 + >8 + 24 <8 OXA-1-like N.D.
B1 Urine HAI ≥32 R 4 ≥128 >64 R >64 R 16 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 ≥320 R P.Z. + >8 + 26 <8 OXA-1-like N.D.
B2 Urine HAI ≥32 R ≥32 R 8 >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 ≤20 P.Z. + >8 + 22 <8 N.D. N.D.
B3 Urine HAI ≥32 R ≥32 R ≥128 R >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≤20 P.Z. + P.Z. + 24 <8 CTX-M Grp1 + OXA-1-like N.D.
B4 Respiratory HAI ≥32 R 16 64 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≤20 P.Z. + >8 + 24 <8 OXA-1-like N.D.
B5 Respiratory HAI ≥32 R 16 64 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≤20 P.Z. + P.Z. + 24 <8 N.D. N.D.
B6 Urine HAI ≥32 R 16 16 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R P.Z. + P.Z. + 24 <8 OXA-1-like N.D.
B7 Respiratory HAI ≥32 R 16 8 >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 ≤20 P.Z. + P.Z. + 24 <8 CTX-M Grp1 + TEM N.D.
B8 Urine HAI ≥32 R ≥32 R 16 R >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + P.Z. + 17 + <8 OXA-1-like N.D.
B9 Urine HAI ≥32 R ≥32 R 8 >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + >8 + 26 <8 OXA-1-like N.D.
C1 Urine HAI ≥32 R ≥32 R ≥128 R >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + >8 + 24 <8 CTX-M Grp1 + OXA-1-like N.D.
C2 Urine HAI ≥32 R 8 ≤4 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + P.Z. + 24 <8 CTX-M Grp1 + TEM +OXA-1-like N.D.
C3 Urine HAI ≥32 R ≥32 R 32 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + P.Z. + 17 + <8 OXA-1-like N.D.
C4 Urine HAI ≥32 R ≥32 R 16 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + >8 + 16 + <8 OXA-1-like N.D.
C5 Urine HAI ≥32 R ≥32 R ≥128 R >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 40 >8 + P.Z. + 22 <8 OXA-1-like N.D.
C6 Urine HAI ≥32 R ≥32 R 64 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R P.Z. + >8 + 17 + <8 OXA-1-like N.D.
C7 Urine HAI ≥32 R 16 16 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R P.Z. + >8 + 24 <8 OXA-1-like N.D.
C8 Skin and soft tissue HAI ≥32 R ≥32 R 64 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + >8 + 15 + <8 OXA-1-like N.D.
C9 Bloodstream HAI ≥32 R 16 ≤4 >64 R >64 R 16 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 ≥320 R P.Z. + >8 + 24 <8 CTX-M Grp1 N.D.
D1 Urine HAI ≥32 R 4 ≤4 >64 R >64 R 16 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 ≤20 P.Z. + >8 + 20 <8 CTX-M Grp1 N.D.
D2 Skin and soft tissue HAI ≥32 R 16 32 >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R 1 ≥320 R P.Z. + P.Z. + 15 + <8 CTX-M Grp1 + OXA-1-like N.D.
D3 Skin and soft tissue HAI ≥32 R 16 64 >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≤20 P.Z. + P.Z. + 23 <8 TEM + OXA-1-like N.D.
D4 Skin and soft tissue HAI ≥32 R ≥32 R 16 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + P.Z. + 17 + <8 CTX-M Grp1 + OXA-1-like N.D.
D5 Urine HAI ≥32 R ≥32 R ≥128 R >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + >8 + 17 + <8 CTX-M Grp1 + OXA-1-like N.D.
D6 Urine HAI ≥32 R ≥32 R ≥128 R >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R P.Z. + >8 + 24 <8 OXA-1-like N.D.
D7 Skin and soft tissue HAI ≥32 R ≥32 R ≥128 R >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R P.Z. + >8 + 17 + <8 CTX-M Grp1 + OXA-1-like N.D.
D8 Urine HAI ≥32 R 8 ≤4 >64 R >64 R 16 R ≤0,5 ≤0,25 ≤1 ≥4 R ≥8 R ≤0,5 ≥320 R P.Z. + P.Z. + 25 <8 CTX-M Grp1 + TEM N.D.
D9 Urine CAI ≥32 R ≥32 R ≥128 R >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + >8 + 17 + <8 CTX-M Grp1 + OXA-1-like N.D.
E2 Skin and soft tissue HAI ≥32 R ≥32 R 64 >64 R >64 R ≥64 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R >8 + >8 + 17 + <8 CTX-M Grp1 + OXA-1-like N.D.
E3 Urine HAI ≥32 R 16 16 >64 R >64 R 16 R ≤0,5 ≤0,25 ≥16 R ≥4 R ≥8 R ≤0,5 ≥320 R P.Z. + >8 + 15 + <8 CTX-M Grp1 + OXA-1-like N.D.
E4 Skin and soft tissue HAI ≥32 R ≥32 R 32 >64 R 8 R 16 R ≤0,5 ≤0,25 ≥16 R 0,5 1 ≤0,5 ≤20 Inconclusive Inconclusive 9 + >8 + TEM CIT
Legend: AMC = amoxicillin/clavulanic acid; AMP = ampicillin; CIP = ciprofloxacin; CN-cefotetan; CNI = cefotetan/cloxacillin; CT = cefotaxime; CTL = cefotaxime/clavulanic acid;
CXM = cefuroxime; ERT = ertapenem; FOX = cefoxitin; GEN = gentamicin; LVX = levofloxacin; MEM = meropenem; SXT = trimethoprim/sulfamethoxazole; TZ = ceftazidime;
TZL = ceftazidime/clavulanic acid; TZP = piperacillin/tazobactam. R or I-resistant or intermediate susceptibility to the antimicrobial agent or combination; N.D. = not determined;
+ = positive test; HAI = Healthcare-associated infection; CAI = Community-acquired infection.
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Regarding non-β-lactams, antibiotics from all of the strains in the study were susceptible to
tigecycline, a tetracycline. Also, 97% (37/38) of the strains evidenced resistance to fluoroquinolones
(ciprofloxacin and levofloxacin), 71% (27/38) to aminoglycosides (gentamicin and tobramycin), and
only 3% (1/38) to amikacin (data not shown). Of all strains studied, 55% (21/38) were resistant to the
combination of trimethoprim/sulfamethoxazole.
Phenotypic production of ESBLs was confirmed by E-test for 97% (37/38) of the strains. The
remaining 3% (1/38) correspond to the strain that showed inconclusive results in both E-tests.
Cefoxitin (cephamycin) was used as a screening test for AmpCs producers in combination with
E-test. Concerning this antibiotic, 37% of the strains (14/38) were resistant to cefoxitin, while AmpC
E-test confirmation gave only one positive result.
3.3. Molecular Characterization of bla Genes
The evaluation of bla genes was performed by multiplex PCR for TEM, SHV and OXA (TSO),
CTX-M, and plasmid AmpC. In the 38 strains, 49 bla genes were detected, which indicates the
co-production of several bla genes within the same strain.
The detection of bla genes was confirmed in 87% (33/38) of the strains under study. The remaining
13% correspond to isolates that did not amplify any of the studied bla genes (Figure 2).
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Concerning the 37 ESBLs producers detected by E-test, 32 were confirmed by PCR, indicating its
high sensitivity (97%). Among the 49 bla genes detected, 55% (27/49) were blaOXA-1-like, 33% (16/49) were
blaCTX-M group 1, 10% (5/49) were identified as blaTEM, and only one gene, or 2% (1/49), was identified as
blaCIT.
The production of OXA-1-like-type ESBL was found in 71% (27/38) of the isolates, and 44% of the
time (12/27), at least another bla gene was detected in the same microorganism. Conversely, CTX-M-1
group ESBL was found in 42% (13/38) of the strains, but up to 81% of the time (13/16) in co-production
with other types of bla genes.
Among the many bla gene combinations identified in the present study, CTX-M-1 group and
OXA-1-like-type ESBLs were predominant, appearing up to 26% of the time (10/38).
The co-production of blaTEM and blaCIT were detected in the same strain E4 (Figure 3). Although
this strain gave inconclusive E-test results for ESBL, the result obtained from E-test for AmpC was
positive and confirmed by PCR.
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4. Discussion
The high prevalence of ESBLs and plasmid-mediated AmpCs strains of Enterobacteriaceae is a
major concern worldwide [26]. In this study, 38 E. coli strains with reduced susceptibility and high
resistance to 3G cephalosporins were evaluated.
About 97% (37/38) of strains isolated in the present study came from health care facilities. According
to the literature, hospitals are still a setting in which multi-resistant bacteria are predominant [12]. As
mentioned, only one strain was found from a community acquired infection (CAI). Nonetheless, it was
found that the patient carrying such a strain was hospitalized afterwards, thus the fact that it could be
another healthcare acquired infection (HAI) cannot be excluded.
The resistance to different antibiotics classes has been described in ESBL- and
AmpC-producing-strains. Genes conferring resistance to quinolones and aminoglycosides have
been extensively reported in the same plasmid harboring bla genes [18]. These resistance profiles
confine the therapy choices and allow the spread of multi-drug resistant plasmids [17]. In this
study, high resistance to fluoroquinolones (97%, 37/38), to aminoglycosides (71%, 27/38), and to the
trimethoprim/sulfamethoxazole (55%, 21/38) were also found. These results are, in general, highest
when described in previous studies [14,19], however, they are corroborated by other Portuguese
studies [7,9,18,37], suggesting a local resistance profile that may be due to the spread of these
multi-drug resistance plasmids in Portugal. Besides this extended resistance profile, all strains
exhibited susceptibility to tigecycline. This result may be due to the fact that genes encoding to
tetracyclines resistance are less frequently described in plasmid-borne ESBLs and AmpCs than other
classes of antibiotic encoding genes [8,17,38].
Regarding β-lactams antibiotics, all strains were resistant to all β-lactams antibiotics tested, with
the exception of carbapenems, which were suggestive a priori of the presence of ESBL or AmpC
enzymes in such isolates [34,39]. In this study, ESBL E-tests offered a positive result for 97% (37/38) of
the strains examined, pointing out a phenotype of ESBLs. These results were confirmed by molecular
methods in 32 of the 37 strains, indicating the high sensitivity (97%) of E-tests. Therefore, E-tests are
recommended by Clinical and Laboratory Standards Institute (CLSI) and the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) for phenotypic detection of ESBLs, and they are widely
used in clinical laboratories and research studies [17,34,39–41].
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However, an inconclusive result (1/38) was found using ESBL E-test. According to Mohanty et al.
(2010), this inconclusive result may be due to the co-production of β-lactamases, since the production
of AmpCs may mask the ESBLs production in phenotypic tests [20].
The susceptibility to cefoxitin was applied as a phenotypic screening method for AmpC-type
β-lactamase production, as referred to in several studies [21,22,26,42,43]. Resistance to cefoxitin was
verified in 37% (14/38) of the strains. Mohanty et al. (2010) and Oteo et al. (2010) reported that ESBL
β-lactamases are unable to hydrolyze cephamycins [20,26]. However, Bradford et al. (2001) showed
that resistance to cephamycins, similar to cefoxitin, may be found in the presence of ESBL enzymes, but
suggests that the loss of an outer membrane porin protein may be the cause [40]. In 2009, Fernandes et al.
reported high levels of cefoxitin resistance within strains expressing ESBLs in Portugal [44].
As mentioned, AmpC E-test used for phenotypic confirmation of AmpC-type β-lactamase
production revealed one positive result only. This result was obtained in the same strain (E4) that
exhibited an inconclusive result on ESBL E-tests, corroborating the hypothesis of co-production of
ESBL and AmpC enzymes. This result was confirmed by molecular methodology for the detection
of the blaTEM by TSO multiplex PCR and the blaCIT was by AmpC multiplex PCR (Figure 2).
The co-production of these β-lactamases has been reported in sporadic cases, mainly in strains
of E. coli and K. pneumoniae [19]. The TEM β-lactamases were considered the most widespread
ESBLs until the first 5 years of the last decade by many researchers [9,33,40,44], being substituted
with the growing group of CTX-M and plasmid-mediated AmpC β-lactamases, mainly the CMY-2
variant [14,38].
Other cefoxitin-resistant strains that presented a negative result on E-test AmpC did not amplify
any blaAmpC genes. Therefore, AmpC E-test exhibited a better performance as a phenotypic detection
method for AmpC β-lactamases with 100% sensitivity and 100% specificity compared to the cefoxitin
screening method, which yielded results of 100% sensitivity but only 65% specificity. These results are
contrary to other studies [35,45]. Polsfuss et al. (2011) reported that although the cefoxitin screening
showed a lower specificity (78.7%), it evidenced a higher sensitivity (97.4%) than AmpC E-test (77.4%),
proposing a flow chart for AmpC detection with cefoxitin resistance as a screening method and the
cefoxitin/cloxacillin combination as a confirming phenotypic assay [35]. The ambiguous results obtained
may be due to the lower number of isolates evaluated in this study, requiring further investigation.
Although the phenotypic methods are frequently applied in the workflow of clinical laboratories,
the molecular biology methods remain the gold standard for β-lactamase detection and identification,
and allow for epidemiological knowledge [44]. The evaluation of bla genes was performed by several
multiplex PCR recipes, allowing for the characterization of 87% (33/38) of the strains (Figure 2). In the
remaining 13% (5/38), it was not possible to amplify any of the analyzed bla genes. The lack of
amplification may be explained by the presence of a possibly new enzyme, due to the high rate of
mutations bla genes [36,46].
The molecular methods allowed the identification of a total of 49 bla genes. Approximately 55%
(27/49) were blaOXA-1-like, 33% (16/49) were blaCTX-M group 1, and 10% (5/49) were identified as blaTEM.
The present work demonstrated a predominance of blaOXA-1-like followed by blaCTX-M group 1, and a
decrease of frequency of blaTEM genes. These results were in agreement with those previously reported
by other Portuguese studies in concern to the increased occurrence of OXA-1-like and CTX-M ESBLs
and the decrease of frequency of the SHV variants (not found at all in the present study) [9,18,37].
However, one of main observations of this study is the predominance of blaOXA-1-like genes at 55%
(27/49), which has never been described before in the country. This may come from an epidemiological
change or from an endemic phenomenon in the Serra da Estrela region and may require further
detailed studies.
The only blaAmpC gene detected was an AmpC-CIT. According to literature, CMY-2 (a CIT variant)
is the most frequent AmpC from E. coli [26]. In countries such as the United States and Canada, the
CIT-type AmpC has been widely reported in recent years [14]. Baudry et al. reported the presence of
the CMY-2 variant in 96% of the AmpC-type β-lactamase E. coli producers [38]. Also, Woodford et al.
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(2007) described a frequency of 44% of CIT-type AmpC E. coli producers in European countries, such
as the United Kingdom and Ireland [47]. In Spain, Oteo et al. (2010) reported the emerging spread
of this variant when they found that 71% of the β-lactamases were of the CMY-2-type [26]. The high
frequency of CIT-type AmpC worldwide and the geographical proximity between the study country
with Spain, where the spread of this variant is emerging, seem to corroborate the discovery of the
CIT-producing strain in this study.
Almost half (45%) of the 27 blaOXA-1-like found were detected in co-production with other enzymes.
According to the literature, the production of OXA-1-like-type β-lactamases is usually detected in cases
of co-production of β-lactamases due to their lower hydrolytic activity [15,18].
The most common combination, found in 26% (10/38) of the strains, was the CTX-M-1 group with
OXA-1-like-type (Figure 2). This outcome may be supported by the fact that CTX-M-15 (belonging
to CTX-M group 1) was commonly found in co-production with OXA-30 (OXA-1-like variant) [48].
This association has been described by several authors in different countries, such as India, the United
Kingdom, Canada, and Portugal [18].
5. Conclusions
The distribution of E. coli strains harboring different variants of broad-spectrum and
plasmid-mediated β-lactamases, such as ESBL and AmpC, is still a concerning issue in the Portuguese
territory. Molecular identification of ESBLs and AmpCs by PCR allows for comprehension of the local
epidemiology, but these tests are expensive. Specialized personnel and equipment are required and
they are usually implemented for reference or for investigative laboratories. The phenotypic systems
applied in this study may be considered a good alternative for molecular detection of ESBL and AmpC
β-lactamases. One of the major constraints and criticisms of the present work may be the fact that we
do not confirm the identity of the genetic sequence of the amplified genes by means of sequencing
methods. Nevertheless, from the point of view of our healthcare ecology, this study improves greatly
upon the knowledge, since it is the first time that this population is studied at the genotype level,
with a substantial difference having already been found—based only on the categorization of the
main enzymes present—comparative to the frequency and type of enzymes that occur in the rest of
the country.
In the Serra da Estrela region, a predominance of OXA-1-like enzymes were detected, which may
suggest an epidemiological shift of bla genes dissemination, or the existence of an endemic phenomenon
in the Serra da Estrela, Portugal.
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